1582-4934/asset/olbannerleft.gif?v=1&s=9ac4fbc1c8dd6b354380356601e09fc12424db35)
1582-4934/asset/olbannerright.gif?v=1&s=cd3126c456d5857b7dbedcf7ab88bbd934f98dcc)
Original Article
You have open access to this content
Changes in type-specific human papillomavirus load predict progression to cervical cancer
Article first published online: 13 DEC 2012
DOI: 10.1111/j.1582-4934.2012.01631.x
© 2012 The Authors Journal of Cellular and Molecular Medicine © 2012 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Total views since publication: 138
Additional Information
How to Cite
Depuydt, C. E., Criel, A. M., Benoy, I. H., Arbyn, M., Vereecken, A. J. and Bogers, J. J. (2012), Changes in type-specific human papillomavirus load predict progression to cervical cancer. Journal of Cellular and Molecular Medicine, 16: 3096–3104. doi: 10.1111/j.1582-4934.2012.01631.x
Publication History
- Issue published online: 13 DEC 2012
- Article first published online: 13 DEC 2012
- Accepted manuscript online: 14 SEP 2012 08:15AM EST
- Manuscript Accepted: 3 SEP 2012
- Manuscript Received: 1 MAR 2012
Funded by
- Biokring II vzw. Grant Number: R11-007
- Abstract
- Article
- References
- Cited By
- Cumulative Usage
References
- 1, , , et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55: 244–65.
- 2, , , et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12–9.
- 3, , , et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999; 354: 20–5.
- 4, , . The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007; 7: 11–22.
- 5, . Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol. 2007; 212: 356–67.
- 6, , , et al. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006; 24: S3-78-S3/89.
- 7, , , et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006; 119: 1095–101.
- 8, , , et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010; 11: 249–57.
- 9, , . Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer. 2004; 112: 854–9.
- 10, , , et al. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol. 2006; 102: 54–60.
- 11, , , et al. Is human papillomavirus viral load a clinically useful predictive marker? A longitudinal study. Cancer Epidemiol Biomarkers Prev. 2010; 19: 832–7.
- 12, , , et al. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer. 2007; 121: 2787–93.
- 13, , , et al. Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis. 2011; 203: 1425–33.
- 14, , , et al. Human Papillomavirus (HPV) type 16 and type 18 DNA Loads at Baseline and Persistence of Type-Specific Infection during a 2-year follow-up. J Infect Dis. 2009; 200: 1789–97.
- 15, , , et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer. 2002; 98: 590–5.
- 16, , , et al. Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol. 2006; 35: 270–7.
- 17, , , et al. Kinetics of DNA load predict HPV 16 viral clearance. J Clin Virol. 2011; 51: 44–9.
- 18, , , et al. Human papillomavirus 16 load and E2/E6 ratio in HPV16-positive women: biomarkers for cervical intraepithelial neoplasia >or=2 in a liquid-based cytology setting? Cancer Epidemiol Biomarkers Prev. 2009; 18: 2992–9.
- 19, , , et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008; 100: 513–7.
- 20, , , et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010; 102: 1478–88.
- 21, , , et al. Persistence of Type-Specific Human Papillomavirus Infection and Increased Long-term Risk of Cervical Cancer. J Natl Cancer Inst. 2011; 103: 1387–96.
- 22, , , et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 2006; 66: 10630–6.
- 23, , , et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007; 195: 1582–9.
- 24. Vanden Broeck D, Ruymbeke MJ et al. Prior knowledge of HPV status improves detection of CIN2+ by cytology screening. Am J Obstet Gynecol. 2011; 205(569): e1–7.
- 25, , , et al. European guidelines for clinical management of abnormal cervical cytology, part 2. Cytopathology. 2009; 20: 5–16.
- 26, , , et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology. 2008; 19: 342–54.
- 27, , , et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology. 2007; 18: 133–9.
- 28, , , et al. Improved endocervical sampling and HPV viral load detection by Cervex-Brush Combi. Cytopathology. 2006; 17: 374–81.
- 29, , , et al. High-throughput detection, genotyping and quantification of the human papillomavirus using real-time PCR. Clin Chem Lab Med. 2011; 50: 655–61.
- 30, , , et al. MedCalc: a new computer program for medical statistics. Comput Methods Programs Biomed. 1995; 48: 257–62.
- 31, , , et al. Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J Cell Mol Med. 2007; 11: 881–91.